Kosho Murayama
Osaka, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Ceralasertib, an ATR kinase inhibitor, as monotherapy in Japanese patients with advanced solid malignancies: Results from a phase 1 study.
Journal: Investigational new drugs
Published: August 05, 2025
Quantifying CD73 expression after chemotherapy or chemoradiotherapy in esophageal squamous cell carcinoma.
Journal: Discover oncology
Published: November 26, 2024
Safety and efficacy of acalabrutinib and obinutuzumab in treatment-naive chronic lymphocytic leukemia: a Japanese phase 1 study.
Journal: Leukemia & lymphoma
Published: July 02, 2024
Safety and pharmacokinetics of imaradenant (AZD4635) in Japanese patients with advanced solid malignancies: a phase I, open-label study.
Journal: Cancer chemotherapy and pharmacology
Published: June 29, 2023
Safety, tolerability, pharmacokinetics and preliminary antitumour activity of an antisense oligonucleotide targeting STAT3 (danvatirsen) as monotherapy and in combination with durvalumab in Japanese patients with advanced solid malignancies: a phase 1 study.
Journal: BMJ open
Published: October 21, 2022
Safety, tolerability, pharmacokinetics, and antitumour activity of oleclumab in Japanese patients with advanced solid malignancies: a phase I, open-label study.
Journal: International journal of clinical oncology
Published: March 08, 2022
Detection of Biomarkers for Epithelial-Mesenchymal Transition with Single-Cell Trajectory Inference.
Detection of Biomarkers for Epithelial-Mesenchymal Transition with Single-Cell Trajectory Inference.
Journal: Frontiers in bioscience (Landmark edition)
Published: March 05, 2022
FEAT enhances INSL3 expression in testicular Leydig cells.
Journal: Genes to cells : devoted to molecular & cellular mechanisms
Published: July 24, 2018
Showing 1-9 of 9
Last Updated: 09/26/2026